Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In anticancer drug development, the combined use of two drugs is an important strategy to achieve greater therapeutic success. Often combination studies are performed in animal (mostly mice) models before clinical trials are conducted. These experiments on mice are costly, especially with combination studies. However, experimental designs and sample size derivations for the joint action of drugs are not currently available except for a few cases where strong model assumptions are made. For example, Abdelbasit and Plackett proposed an optimal design assuming that the dose–response relationship follows some specified linear models. Tallarida et al. derived a design by fixing the mixture ratio and used a t‐test to detect the simple similar action. The issue is that in reality we usually do not have enough information on the joint action of the two compounds before experiment and to understand their joint action is exactly our study goal. In this paper, we first propose a novel non‐parametric model that does not impose such strong assumptions on the joint action. We then propose an experimental design for the joint action using uniform measure in this non‐parametric model. This design is optimal in the sense that it reduces the variability in modelling synergy while allocating the doses to minimize the number of experimental units and to extract maximum information on the joint action of the compounds. Based on this design, we propose a robust F‐test to detect departures from the simple similar action of two compounds and a method to determine sample sizes that are economically feasible. We illustrate the method with a study of the joint action of two new anticancer agents: temozolomide and irinotecan. Copyright © 2003 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
Cited by
Systems biology and combination therapy in the quest for clinical efficacy
Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio817 · Cited by 570
“Considerable attention has therefore been devoted to sparse-search strategies that maximize statistical power while minimizing the number of trial”
BackgroundStrategies for optimizing combinations of molecularly targeted anticancer agents
Dancey, J. E., & Chen, H. X. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2089 · Cited by 365
Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy
Lee, J. J., Kong, M., Ayers, G. D., & Lotan, R. (2007) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400701199593 · Cited by 135
“( 2003 ) proposed an optimal experimental design in the sense that it reduces the variability in modeling synergy while allocating the doses to minimize the sample size and to extract maximum information on the joint action of the drugs.”
BackgroundAssessing interactions for fixed-dose drug combinations in tumor xenograft studies
Wu, J., Tracey, L., & Davidoff, A. M. (2012) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2011.556285 · Cited by 21
Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies
Wu, J. (2013) · Pharmaceutical Statistics · doi:10.1002/pst.1559 · Cited by 10
Metadata
- Authors
- Tan, M., Fang, H., Tian, G., & Houghton, P. J.
- Venue
- Statistics in Medicine
- Publisher
- Wiley
- Published
- 2003-06-12
- Volume
- 22
- Issue
- 13
- Pages
- 2091-2100
- ISSN
- 0277-6715 (ISSN-L)
- 1097-0258
- OpenAlex
- W2163046746
- Cited by
- 59
- References
- 1
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.